Clostridioides difficile Infection in Patients Undergoing Acid-Suppressive Treatment: A Large Cohort Study with Propensity Score Matching
Digestive Diseases · 2025
DOI: 10.1159/000547573 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Digestive Diseases, 2025. Verfasst von Ilsoo Kim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, ilsookim…. Hauptthemen laut MEDLINE: Clostridium Infections, Proton Pump Inhibitors, Histamine H2 Antagonists, Clostridioides difficile. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Clostridioides difficile infection (CDI) is a significant concern in patients undergoing acid-suppressive therapy. This study aimed to evaluate and compare the risk of CDI in patients treated with proton pump inhibitors (PPIs), histamine 2 receptor antagonists (H2RAs), and potassium-competitive acid blockers (tegoprazan).
Methods
This retrospective observational cohort study evaluated 606,460 individuals who were prescribed PPIs, H2RAs, or tegoprazan for more than 7 days, resulting in 22,431 matched individuals after propensity score matching. The primary outcome was CDI incidence within 12 weeks of medication use.
Results
Patients receiving PPIs exhibited a significantly higher relative risk (RR) (RR: 1.86; 95% confidence interval [CI]: 1.18–2.91) of developing CDI than those receiving H2RAs. Tegoprazan showed no significant increase in CDI risk (RR: 1.07; 95% CI: 0.64–1.79) compared to H2RAs. The risk of CDI increased with a longer duration of acid suppressant use. No dose-dependent differences in CDI occurrence were observed across PPI doses and no significant differences were found in the incidence of severe CDI among the groups.
Conclusions
PPIs are associated with a higher risk of CDI than H2RAs. These findings highlight the need for careful selection of acid-suppressive therapies, particularly in high-risk populations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, ilsookim86@gmail.com.
- Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
- Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Zitieren
APA
Kim, I., Kim, J. S., Park, J. M., Cheung, D. Y., Kim, T. H., Chung, W. C., Oh, J. H., Choi, H. H., & Lee, S. W. (2025). Clostridioides difficile Infection in Patients Undergoing Acid-Suppressive Treatment: A Large Cohort Study with Propensity Score Matching. Digestive Diseases. https://doi.org/10.1159/000547573
Vancouver
Kim I, Kim JS, Park JM, Cheung DY, Kim TH, Chung WC, et al. Clostridioides difficile Infection in Patients Undergoing Acid-Suppressive Treatment: A Large Cohort Study with Propensity Score Matching. Digestive Diseases. 2025. doi:10.1159/000547573
BibTeX
@article{Kim2025,
author = {Kim, Ilsoo and Kim, Joon Sung and Park, Jae Myung and Cheung, Dae Young and Kim, Tae Ho and Chung, Woo Chul and Oh, Jung-Hwan and Choi, Hyun Ho and Lee, Seung-Woo},
title = {Clostridioides difficile Infection in Patients Undergoing Acid-Suppressive Treatment: A Large Cohort Study with Propensity Score Matching},
journal = {Digestive Diseases},
year = {2025},
doi = {10.1159/000547573}
}
EUVIMED